Successful vaccine irnrnunotherapy. An exciting novel approach to cancer treatment

Global cancer spread to pandemic proportions, has reinforced the importance of disease surveillance and prevention programs, and has provided the stimulus for greater resources in vaccine development. Many reports from phase I or II trials indicate that both partial and complete responses have been observed, with little or no toxicity, in a small proportion of vaccine recipients. Future prospects will be to increase basic knowledge of immunogenic tumor antigens to vaccine administration, which will make the cancer patient develop an immune response able to induce tumor regression. Clinical trials already under way in patients with malignant diseases may yield more definitive conclusions.

Cancer; Vaccine; Immunotherapy

[1] Rock K.L., Rothstein L., Benacerraf B.: "Analysis of the association of peptides of optimal length to class I molecules on the surface of cells". Proc. Natl. Acad. Sci USA, 1992, 89, 8918.

[2] Rosenberg S.A., Yang J.C., Schwartzentruber D.J. et al.: "Immunologic and therapeutic evaluation of a synthetic peptide vaccme for the treatment of patients with metastatic melanoma". Nat. Med., 1998, 4, 321.

[3] Tsang K. Y., Zaremba S., Nieroda C.A. et al.: " Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine". J. Natl. Cancer Inst., 1995, 87, 982.

[4] Boon T., Coulie P.O., Yan den Eynde B.: "Tumor antigens recognized by T cells". lmmunol. Today, 1997, 18, 267.

[5] Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K. et al.: "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity". Proc. Natl. Acad. Sci USA, 1993, 90, 3539.

[6] Golumbek P.T., Lazenby A.J., Levitsky H.l., Jaffee L.M., Karasuyama H., Baker M. et al.: " Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4". Science, 1991, 254, 713.

[7] Renner C., Kubuschok B., Triimber L., Pfreundschuh M.: "Clinical approaches to vaccination in oncology". Ann. Hematol., 2001, 80, 255.

[8] EspmoLa-Delgado I.： “Cancer Vaccmes”. The Oncologist, 2002, 7 (suppl. 3)，20.

[9] Murakami M., Gurski K.J., Steller M.A.: "Human papillomavirus vaccines for cervical cancer". J. Jmmunother., 1999, 22, 212.

[10] Parkin D.M., Pisani P., Ferlay J.: " Estimates of worldwide incidence from 25 major cancers in 1990". int. J. Cancer, 1999, 80, 827.

[11] Pisani P., Parkin D.M., Bray F. et al.: "Estimates of the worldwide mortality from 25 cancers in 1990". Int. J. Cancer. 1999, 83, 18.

[12] Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R.: " T he E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for tran、formation of primary human keratinocytes". J. Viral., 1989, 63, 4417.

[13] Wemess B.A., Levine A.J., Howley P.M.: "Association of human papillomavirus types 16 and 18 E6 proteins with p53". Science, 1990, 248, 76.

[14] Kimbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T.: "Papillomavirus Ll major capsid protein self-assembles into viruslike particles that are highly immunogenic". Proc. Natl. Acad. Sci USA, 1992, 89, 12180.

[15] Kimbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L. et al.: " Efficient self-assembly of human pap仆lomavirus type l 6L, and L,-L, into virus-like particles". J. Viral., 1993, 67, 6929.

[16] Harro C.D., Pang S., Roden R.R.B.S., Hildesheim A., Wang Z., Dillner J. et al.: "A safety and immunogenicity trial of a humam papillomavirus type 16 L1 virus-like particle vaccine in healthy young adult human volunteers (abstract)". 18'6 International Papillomavirus Conference, Barcelona, Spain 2000; Program and Abstracts Book, 362.

[17] Poland G.A., Hagensee M.E., Koutsky L.A., Garrett S., Suhr G., Smith J.F. et al.: "A randomized, double-blind, placebo-controlled trial of the immunogenicity and reactogenicity of a novel HPY 16 vaccine: preliminary results (abstract)". 18'" International Papillomavims Conference, Barcelona, Spain 2000; Program and Abstracts Book, 363.

[18] Fife K.H., Brown D.R., Wheeler C.M., Schiff P.R.: "A dose-ranging study of the safety and immunogenicity profiles of an HPV 11 L, VLP candidate vaccine in young healthy women (abstract)". 18"'International Papillomavirus Conference, Barcelona, Spain, 2000. Program and Abstracts Book, 364.

[19] Balsley J.F., Connor E.M., Reichman R.C., Dubin G., Strouse R.J., Suzich J.A., Koening S.: "Progress in the development of human papillomavirus vaccines for HPV-11 and HPV-16/18 and mapping of a critical neutralizing epitope (abstract)". 18"'International Papillomavirus Conference, Barcelona, Spain 2000. Program and Abstracts Book, 366.

[20] Da Silva D.M., Eiben G.L., Fausch S.C., Wakabayashi M.T., Rudolf M.P., Velders M.P., Kast W.M.: " Cervical cancer vaccmes: emerging concepts and developments". J. Cell. Physiol. (review), 2001, 186 (2), 169.

[21] Hilders C.G., Ras L., Van Eendenburg J.D., Nooyen Y., Fleuren G.J.: "Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma". int. J. Cancer, 1994, 57, 805.

[22] Chen L., Thomas E.K., Hu S., Hellstrom I., He11strom K.E.: "Human papillomavirus type 16 nucleoprotein E, is a tumor reJection antigen". Proc. Natl. Acad. Sci USA, 1991, 88, 110.

[23] Chen L., Mizuno M.T., Singha! M.C., Hu S., Galloway D.A., Hellstrom I., Hellstrom K.E.: "Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16". J. Jmmunol., 1992, 148, 2617.

[24] Steller M.A., Gurski K.J., Murakami M., Daniel R.W., Shah K.V., Celis E. et al.: "Cell-mediated immunocological responses in cervical and vaginal cancer patients immunized with a lipittated epitope of human papillomavirus type 16 E,". Clin. Cancer Res., 1998, 4, 2103.

[25] Van Oriel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., Van Rossum A.B. et al.: "Vaccination with HPV 16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase 1-11 trial". Eur. J. Cancer, 1999, 35, 946.

[26] Da Silva D.M., Velders M.P., Rudolf M.P., Sch仆!er J.T., Kast W.M.: "Papillomavirus virus-like particles as anticancer vaccines" Curr. Opin. Malec. Ther., 1999, 1, 82.

[27] Tuting T., Gambotto A., DeLeo A., Lotze M.T., Robbins P.O., Storkus W.J.: "Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice". Cancer Gene Ther., 1999, 6, 73.

[28] Shi W., Bu P., Liu J., Polack A., Fisher S., Qiao L.: "Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity". J. Viral., 1999, 73, 7877.

[29] Chen C.H., Wang T., Hung C., Yang Y., Young R.A., Pardoll D.M., Wu T.C.: "Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP 70 gene". Cancer Res., 2000, 60, 1035.

[30] Hung C., Hsu K., Cheng W., Chai C., He L., Ling M., Wu T.C.: "Enhancement of DNA vaccine potency by linkage of antigen gene to a Flt3-ligand gene (abstract)". 18th International Papillomavirus Conference, Barcelona, Spain 2000; Program and Abstract Book, 434.

[31] Chu N.R., Wu H.B., Wu T. et al.: "Immunotherapy of a human pap仆lomavirus (HPV) type 16 E7-expressing tumor by admm1stration of fusion protein comprising Mycobacterium bovis bacilli Calmette-Guerin (BCG) hsp65 and HPV 16 ET'. Clin. Exp Immunol., 2000, 121, 216.

[32] Ji H., Wang T.L., Chen C.H. et al.: "Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7 - expressing tumors". Hum Gene Ther., 1999, 10, 1227.

[33] Liu D.W., T sao Y.P., Kung J.T. et al.: "Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer". J. Viral., 2000, 74, 2888.

[34] Borysiewicz L.K., Fiander A., Nimako M., Man S. et al.: "A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins immunotherapy for cervical cancer". Lancet, 1996, 347, 1523.

[35] Schultz J.: "Success of vaccine offers promise of cervical prevention". J. Natl Cancer Inst., 2003, 95 (2), 102.

[36] Scanlan M.J., Jager D.: "Challenges to the development of antigen-specific breast cancer vaccines". Breast Cancer Res., 2001, 3, 95.

[37] Weiss R.B., Gill G.G., Hudis C.A.: "An on site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications". J. Clin. Oneal., 2001, 19, 2771.